Cargando…

Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias

Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochondrial dysfunction and perturbed calcium homeostasis have been identified as key events...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lane, Rachel F, Shineman, Diana W, Fillit, Howard M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308025/ https://www.ncbi.nlm.nih.gov/pubmed/22236739 http://dx.doi.org/10.1186/alzrt99

Ejemplares similares

Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
por: Lane, Rachel F, et al.
Publicado: (2013)

A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA
por: Lee, Linda H, et al.
Publicado: (2010)

Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery
por: Friedman, Lauren G, et al.
Publicado: (2014)

Novel strategies for the prevention of dementia from Alzheimer's disease
por: Shineman, Diana W., et al.
Publicado: (2009)

Meeting the unique challenges of drug discovery for neurodegenerative diseases
por: Shineman, Diana W, et al.
Publicado: (2009)

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
por: Shineman, Diana W, et al.
Publicado: (2013)

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies
por: Shineman, Diana W, et al.
Publicado: (2011)

A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
por: Karran, Eric, et al.
Publicado: (2014)

Sleep in Alzheimer's Disease–Beyond Amyloid
por: Holth, Jerrah K., et al.
Publicado: (2016)

Governance of portfolios, programs, and projects
por: Project Management Institute
Publicado: (2016)

Digital drug discovery
por: Goldman, Michael A
Publicado: (2005)

Aging and drug discovery
por: Bakula, Daniela, et al.
Publicado: (2018)

Anti-amyloid aggregation activity of novel carotenoids: implications for Alzheimer’s drug discovery
por: Lakey-Beitia, Johant, et al.
Publicado: (2017)

Multidimensional evaluation in clinical diagnosis of Alzheimer’s disease: genetic risk in Alzheimer’s disease and neurodegenerative dementias
por: Bruni, A C
Publicado: (2010)

Driving Project, Program, and Portfolio Success
por: Maltzman, Richard, et al.
Publicado: (2015)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
por: Matthews, Dawn C., et al.
Publicado: (2021)

Cover's universal portfolio, stochastic portfolio theory, and the numéraire portfolio
por: Cuchiero, Christa, et al.
Publicado: (2018)

To metabolomics and beyond: a technological portfolio to investigate cancer metabolism
por: Danzi, Federica, et al.
Publicado: (2023)

Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease
por: Heller, Gabriella T., et al.
Publicado: (2020)

Lessons from a Rare Familial Dementia: Amyloid and Beyond
por: Cantlon, Adam, et al.
Publicado: (2015)

Amyloid PET imaging: applications beyond Alzheimer’s disease
por: Catafau, Ana M., et al.
Publicado: (2015)

Beyond amyloid: New approaches to Alzheimer's disease treatment
Publicado: (2020)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia
por: Ho, Yuen-Shan, et al.
Publicado: (2011)

Dementia in the oldest old: Beyond Alzheimer disease
por: Pierce, Aimee L., et al.
Publicado: (2017)

Middle managers in program and project portfolio management
por: Blomquist, Tomas, et al.
Publicado: (2006)

The standard for risk management in portfolios, programs, and projects
por: Project Management Institute
Publicado: (2019)

Interpersonal Skills for Portfolio, Program, and Project Managers
por: Levin, Ginger
Publicado: (2010)

Project, program and portfolio approaches to strategic transformation
por: Jiang, James
Publicado: (2019)

Latest advances in aging research and drug discovery
por: Bakula, Daniela, et al.
Publicado: (2019)

Meeting Report: Aging Research and Drug Discovery
por: Meron, Esther, et al.
Publicado: (2022)

Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrP(C) binding and downstream pathways
por: Grayson, James D., et al.
Publicado: (2021)

Neurodegenerative diseases: complexity of clinical phenotypes in genetic models of alzheimer’s disease and frontotemporal dementia
por: Bruni, A C
Publicado: (2010)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Translating the biology of aging into novel therapeutics for Alzheimer disease
por: Hara, Yuko, et al.
Publicado: (2019)

Portfolio optimization for seed selection in diverse weather scenarios
por: Marko, Oskar, et al.
Publicado: (2017)

Relational diversity in social portfolios predicts well-being
por: Collins, Hanne K., et al.
Publicado: (2022)

Circular plant peptides as templates for GPCR drug discovery?
por: Koehbach, Johannes, et al.
Publicado: (2011)

Stem cells in drug discovery, regenerative medicine and cancer
por: Rountree, C Bart
Publicado: (2011)

Utilizing traditional Chinese for the discovery of efficacious new drugs
por: Bender, Andreas
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g5br1315q3uo8cgi849c4h51kp